Company Profile. Welcome at VitaK Innovation in Life Science. We create unique innovation tools for better healthcare
|
|
- Camilla Willis
- 5 years ago
- Views:
Transcription
1 Company Profile Welcome at VitaK Innovation in Life Science We create unique innovation tools for better healthcare
2 Introduction Mission Statement History Management Team Divisions Patents Contact
3 Mission Statement Our mission is to improve public health and the individual quality of life by developing unique, innovative concepts and products! We create unique innovation tools for better healthcare
4 Our History 1988: The Cardiovascular Research Institute Maastricht was founded 2001: Associate Professor Dr. Cees Vermeer founded VitaK Innovation in Life Science 2001: Setting up the division "Innovation and Research" 2002: Setting up the division Clinical Research Organisation"
5 Our History (continued 1) 2006: Our available expertise and infrastructure for executing Human Intervention Trials was made available for third parties in the food and pharmaceutical area. 2007: A Consultancy branch for the nutritional and pharmaceutical industry was established, with senior scientists providing consultancy on a regular basis. 2010: VitaK Innovation in Life Science reported a conformation-specific Assay for Vascular Matrix Gla-Protein (MGP) which is predictive for cardiovascular mortality both in various patient groups and in the healthy population.
6 Our History (continued 2) 2014: Opening of our office in the United Arab Emirates 2016: Introduction Vita K Meter 2016: Introduction of prototype TransCare 2017: Introduction of prototype Nephro-K 2017: Introduction StiffnoGraph
7 Management Team Founder: Associate Professor Dr. Cees Vermeer (presently retired) has dedicated 40 years of his scientific career to disease prevention by optimal nutrition. His research has formed the basis for the Triage principle: long term minimal micronutrient insufficiencies form a strong risk factor for age-related diseases. He is a Key Opinion Leader in the field of vitamin K and author of over 420 papers in the international scientific press. CEO: Drs. Mehrdad Omidvar has more than 24 years working experience (national and international) in several fields: Care & Cure, Investment, Pharma, R&D, Innovation, Life Science, E-health, Medical Device, POC and IVD, Knowledge Valorisation, Clinical Nutrition and Contract Research Organization (CRO). He was also Director UAE of Maastricht University and Director B. D. at School for Cardiovascular Diseases, Maastricht University. CSO: Professor Dr. Stephane Heymans combines clinics and research in Cardiology since He leads a clinical care and research program in heart failure, in particular non-ischemic dilated cardiomyopathy, myocarditis and heart failure with preserved ejection fraction at the Maastricht University Medical Centre. His research looks for innovative techniques for the early diagnosis and refined therapies of these cardiovascular diseases. Genetics, omics, fibrosis and immunology are his main topics of research. Appointed as Professor of Cardiomyopathies within the Netherlands Heart Institute, the Maastricht University.
8 Management Team Vice President R&D: Dr. Pamela Kleikers studied Medicine at Maastricht University. After obtaining her medical degree in 2009, she started to work at the Atrium Medisch Centrum in Heerlen. In 2014 she got her PhD at Maastricht University at the department of Pharmacology. She continued working as a postdoctoral researcher at the department of Pharmacology and Personalised Medicine. Next to the research activities, Dr. Kleikers was also involved in teaching and supervision of (bio)medical students of Maastricht University. Operational Director: Mrs. Marjo Knapen studied Biochemistry at the University of Applied Sciences. She joined the VitaK Innovation in Life Sciences in 2001, and before that she has worked for 14 years at the Maastricht University. She is author in more than 85 publications in the international scientific literature. She is also heading the International Center for Human Intervention Studies (ICHIS).
9 Management Team International Commercial Director: Mrs. Ling Leonard has more than 25 years working experience (national and international) in several fields: Care & Cure, Innovation and Medical Device, specialized in cardiopulmonary products. After obtaining her MBA degree at Oklahoma City University, she studied Public Accounting in the USA. Vice President Technical Officer: Mrs. Nivedita Daimiwal works is responsible for the technical scientific process. She has more than 20 years of working experience at the Technical University (Cummins College of Engineering for Women) in India. She obtained her bachelor in Instrumentation and Control and a master in Biomedical Instrumentation. In 2012 she started her PhD at Sathyabama University. She works as Assistant Professor and has more than 35 publications. Her areas of research and expertise are: Sensor design, APG, Non-Invasive Devices, PPG, Biomedical Singnal, ECG and PWV (Pulse Wave Velocity).
10 Divisions 1) Division Medical Devices (POC and IVD) 2) Division Contract Research Organisation 3) Division Research and Development
11 Division Medical Devices (POC and IVD) This division focuses on the development of Near Patient Testing systems and advanced diagnostic solutions. VitaK is improving patient care by providing the medical community with rapid and reliable information at the Point of Care (POC) and In Vitro Diagnostics (IVD), delivering patient information when and where it is needed most. VitaK has developed a number of patented devices that are applied for the assessment of cardiovascular risk and disease, as well as for vitamin K insufficiency.
12 Division CRO Worldwide we are the number one Laboratory in measuring Matrix Gla Protein (MGP), and we are unique in that we can discriminate between active and inactive MGP conformations. Elevated circulating inactive MGP is one of the strongest risk factors for cardiovascular disease and mortality presently known. Since 2001 we have been experts in measuring biomarkers in blood samples generated in research projects, populationbased studies and clinical trials in the field of cardiovascular disease and related diseases.
13 Division CRO (continued) We support pharmaceutical companies, food (including dairy and food supplement) industries, universities, and academic research institutes in performing human intervention studies falling under the Medical Research Involving Human Subjects Act. We offer measuring absorption of active ingredients, as well as effect monitoring on circulating biomarkers and clinical endpoints.
14 Division CRO (continued) VitaK develops and manufactures innovative measurement and control solutions for the Life Science industry, Food and Dairy industry as well as the Pharmaceutical industry. Our areas of expertise are based on many years of applying knowledge in the measurement and control of: Specified ingredients in food Molecular mechanisms of action of specified ingredients Health effects Vitamin K and GLA-proteins
15 Division Research & Development Both fundamental and applied research are the core business of VitaK Innovation in Life Sciences, and besides our own internal research program we offer our expertise in the form of contract research for third parties. Special research topics are health benefits of vitamins and foods, and the development of new disease markers. Other topics include: Cardiovascular disease Calcium and bone metabolism Cartilage disorders Nephrology Dermatology In vitro cell cultures In vitro skin cultures Research environment
16 Patents Patent applications that have recently evolved from our internal research program include: 1. New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation. 2. Prevention and counteraction of diet-induced thrombosis risk. 3. Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation. 4. Improving epidermal skin health. 5. Importance of vitamin K for microvascular integrity and function.
17 Contact Head office: Oxfordlaan EV Maastricht The Netherlands T: +31 (0) E: W: Laboratories: Oxfordlaan EV Maastricht The Netherlands
18 Thank you!
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationImproved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed
PRESS RELEASE 17 August 2016 Improved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed A groundbreaking study, led by experts from Royal Brompton
More informationDIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE
DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE EXECUTIVE SUMMARY Oncologists reviewing blood and tissue test results face the same problems: Is the
More informationIntroduction to Culinary Genomics
Introduction to Culinary Genomics Fusing nutrition science, genomics and the culinary arts Roberta Kline, MD Joe Veltmann, PhD Amanda Archibald, RD ONLINE March 2, 9, 16 & 23 CULINARY GENOMICS: The culinary
More informationHealthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016
Healthy Ageing From Basic Science to Clinical Applications and New Business Jan Sikkema Center for Development and Innovation June 16, 2016 Groningen Broad Research University 11 faculties > 30.000 students
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationOur Research Strategy
Our Research Strategy 2014-2017 Introduction Kidney Research UK has a 52-year legacy in funding excellent research into all aspects of kidney diseases and disorders. Each year over 3.7 million 1 new investments
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationA PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas
A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas Heart Institute Website: www.texasheart.org, www.ccobtexas.org
More informationThe Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
More informationMicar Innovation. Drug Discovery Factory for novel drug molecules
Problem There are so many incurable diseases around the world that need adequate novel compounds for the treatment, like: - Chronic pain still a pandemic in the 21 st century and affecting 1.5bn people
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationform of testing is used and is
Universal Biosensors, Inc. ABN 51 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 9099 Email: info@universalbiosensors.com www.universalbiosensors.com
More informationPersonalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
More informationInnovation Policy in Cross border perspective
Innovation Policy in Cross border perspective Acceleration Agenda in the Euroregion Meus Rhein/ELAT Triangle Basel, 22 February 2008 Jean Severijns (Martin Eurlings, Herman Vrehen) Province of Limburg
More informationPLTW Biomedical Science Medical Interventions Course Outline
Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More informationAdis Journals and Newsletters The premier collection of drug-focused medical journals
adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationMassachusetts Institute of Technology Program on the Pharmaceutical Industry (POPI) The Future of the Pharmaceutical Industry Symposium
Massachusetts Institute of Program on the Pharmaceutical Industry (POPI) The Future of the Pharmaceutical Industry Symposium Pharmacogenomics, Drug Development and the Cost of Health Care December 9 10,
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationPrograma Cooperación Farma-Biotech Neurociencias G79
G79 A Neuroprotective Therapy Barcelona, 15 de febrero 2011 Content 1. The Company 2. The Product a) Therapeutic focus b) Innovative mechanisms of action c) Differential features facing the market d) Current
More informationUnicyte AG, regenerative medicine unit of Fresenius Medical Care, appoints world-leading experts to Scientific Advisory Board
Press Release Media Contact Martin Kunze T +49 6172 609-2115 martin.kunze@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com July 25, 2017 www.freseniusmedicalcare.com
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationFDA s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs) By Roz Sweeney, Ph.D., Nerac Analyst
FDA s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs) By Roz Sweeney, Ph.D., Nerac Analyst Introduction The FDA recently issued updated draft guidance for proposed regulatory changes affecting
More informationClinical Research Programme
Clinical Research Programme The Clinical Research Programme offers a well-defined development path for ambitious young researchers and physicians CHDR s innovative approach and high level of scientific
More informationSenior Clinical Investigator
Senior Clinical Investigator 2009-2014 Elfride De Baere Center for Medical Genetics, Ghent University, Belgium http://www.cmgg.be FKM symposium Brussels 20 November 2014 Curriculum vitae 1989-1996 02.07.1996
More informationPostes vacants. Juin 2008
Postes vacants Juin 2008 - Senior cardiovascular research scientist - Senior scientist, digestive functions - Scientist, appetite and weight management - Engineer on probiotics effects characterization
More information11% of employees are dedicated to R&D. 11 billions IVD market size 3,000 companies 75,000 people employed. 40,000 IVD products
About edma EDMA The European Diagnostic Manufacturers Association is an international, non-profit organisation representing the interests of the European in vitro diagnostics industry at the European and
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationNeue Technologien für die patientennahe personalisierte Diagnostik
Neue Technologien für die patientennahe personalisierte Diagnostik 2014 Dr. Soeren Schumacher, M.B.A. 27th of June 2014 1 A heterogeneous pool 27th of June 2014 2 A heterogeneous pool Personalized Medicine
More informationGlobal leader in predictive diagnostics ASX: PIQ
Corporate Review Sydney Canary Capital 6 th June 2017 Global leader in predictive diagnostics ASX: PIQ 1 Business model Three synergistic business areas Unifying Promarker platform technology - leverage
More information1.0 Background to the organisation
1.0 Background to the organisation The National University of Ireland Galway, the Royal College of Surgeons in Ireland, University College Cork, University College Dublin and Trinity College and their
More informationHigher National Diploma Biomedical Science
BMS is committed to developing scientists for the betterment of our country Higher National Diploma Biomedical Science leading to final year of BSc (Hons) Biomedical Science Committed to supporting students
More informationTHE ROLE OF IMAGING IN DRUG DISCOVERY, DRUG DEVELOPMENT AND IN CLINICAL STUDIES
THE ROLE OF IMAGING IN DRUG DISCOVERY, DRUG DEVELOPMENT AND IN CLINICAL STUDIES THURSDAY, 8 MARCH 2018 TRINITY HALL, TRINITY LANE, CAMBRIDGE, CB2 1TJ LEARNING OBJECTIVES TO UNDERSTAND THE ROLE FOR USING
More informationConcept of Integrated Research Platforms
Concept of Integrated Research Platforms Michal Vlasin UVPS Brno, Czech Republic Lumir Krejci October 21, 2010 INTEGRATED RESEARCH PLATFORMS AC: Animal Center CBCE: Center of Biomolecular and Cellular
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationExecutive Search. Chief Standards Officer
Executive Search Chief Standards Officer Client Overview Sterling Martin Associates has been retained by the Clinical Data Interchange Standards Consortium (CDISC) to search for Chief Standards Officer
More informationHealth Research 2018 Call for Proposals. Application Form*
Health Research 2018 Call for Proposals Application Form* Application Form* Health Research 2018 Call for Proposals la Caixa Foundation *This Form has only an informative function. Applications will be
More informationMSc in Transfusion and Transplantation Sciences
MSc in Transfusion and Transplantation Sciences School of Cellular & Molecular Medicine Prof Marion Scott, Teaching Board Member 1 1 year full-time specialised MSc, or 2-3 year part-time The full-time
More informationBIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials
BIOSCIENTIA Good outcomes are based on good values Central lab services and biomarker analytics for clinical trials BIOSCIENTIA Do you remember when...... US President Ronald Reagan appealed to Michail
More informationVision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University
Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through
More informationUnderstanding Microbial Control in In-Vitro Diagnostics
Microrite, Inc. brings you this unique learning experience in Understanding Microbial Control in In-Vitro Diagnostics; Part of Microrite s step-by-step webinar series. Understanding Microbial Control in
More informationNew Tools for the Enhanced
New Tools for the Enhanced Management of Chronic Disease Based on a Proprietary, Point of Care, Electrochemical Detection System Universal Biosensors Investor Presentation February 2010 1 Important disclaimer
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationBioscientists Do you have the Bayer Spirit?
CropScience HealthCare MaterialScience Business Services Industry Services Technology Services www.mybayerjob.com Bioscientists Do you have the Bayer Spirit? Research and Development, Screening, Toxicology,
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationAn Taoiseach Opens New Research Centres to Benefit Frontline Patient Care
An Taoiseach Opens New Research Centres to Benefit Frontline Patient Care The clinical translational research facility will be a significant development for health care and medical technology sector in
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationMessage from Genentech s Executive Sponsor
Message from Genentech s Executive Sponsor Dear Prospective Fellow: Genentech is excited to be a part of the University of the Pacific s Fellowship in Industry Program (FIP) for Doctor of Pharmacy graduates.
More informationInternational Conference on Biochemistry, Genetics & Molecular Research Theme: An Evolving Science of Life
International Conference on Biochemistry, Genetics & Molecular Research Theme: An Evolving Science of Life About the Conference: Gavin Conferences invites participants from all over the world to attend
More informationTranslational & Molecular Imaging Institute
Translational & Molecular Imaging Institute tmii.mssm.edu Summer 2015 CARDIOVASCULAR IMAGING The Imaging Research Center is the backbone of the Translational & Molecular Imaging Institute at Mount Sinai
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationE&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
More informationOCTIMET. Company Profile
OCTIMET Oncology NV (OCTIMET) is a privately held Belgian based life science company specialized in accelerating the development of oncology therapies by providing rapid clinical proof of concept through
More informationOUR WISH LIST RESEARCH EQUIPMENT
OUR WISH LIST RESEARCH EQUIPMENT YOU CAN MAKE A TANGIBLE DIFFERENCE! The South Australian Health and Medical Research Institute (SAHMRI) is one of the most exciting developments in the field of health
More informationOUR WISH LIST RESEARCH EQUIPMENT
OUR WISH LIST RESEARCH EQUIPMENT WITH YOUR PHILANTHROPIC SUPPORT, WE CAN WORK TOGETHER TO COMPLETE OUR FULLY-FUNCTIONAL FACILITY BY PURCHASING THE CUTTING-EDGE EQUIPMENT AND RESOURCES TO SUPPORT SAHMRI
More informationBasic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.
APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationInnovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint
HIGH-LEVEL CONFERENCE "EXPLORING INNOVATIVE HEALTHCARE THE ROLE OF MEDICAL TECHNOLOGY INNOVATION AND REGULATION" Innovation in medical devices as response to Europe's healthcare challenges Industry's viewpoint
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationGENOMICS: THE KEY TO TOMORROW S TREATMENTS? Jim Sullivan, PH.D. Vice President, Discovery AbbVie
GENOMICS: THE KEY TO TOMORROW S TREATMENTS? Jim Sullivan, PH.D. Vice President, Discovery AbbVie Ideas that Change Healthcare, Kings Fund, 06/10/17 AXGOV171426 Date ofpreparation: October 2017 Genomics
More informationInternational Conference on Engineering Technology & Applied Sciences Theme: Discovery, Invention & Innovation of Technology
International Conference on Engineering Technology & Applied Sciences Theme: Discovery, Invention & Innovation of Technology About the Conference: Gavin Conferences invites participants from all over the
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationKnowing changes everything.
SYRACUSE, NEW YORK CLINICAL UPDATE May 2009 $6.2 million for Stem Cell Research SUNY Upstate s well-established stem cell research program receives a massive boost from NYSTEM. GPS for Prostate University
More informationPharmabiotics: a Regulatory Hurdle in Europe
Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics
More informationNever invest in a business you can t understand.
Presentation for Pre Diagnostics AS: EARLY BIOTECH Never invest in a business you can t understand. Warren Buffett 2 1 INDUSTRIAL APPROACH: GIM Innovation Product Supply side Future oriented requires industrial
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationBiomarkers as an emerging growth area in Denmark
Biomarkers as an emerging growth area in Denmark International Conference on Perspectives in Precision Medicine, Copenhagen March 1, 2018 Kim Holmstrøm, PhD. Chairman of The Danish Biomarker Network R&D
More informationINTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.
1 INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES www.lsmuni.lt 2 3 About Lithuanian University of Health Sciences Lithuanian University
More informationSciTechnol Mediakit. MatheMatics. Research and Reports on. Research Journal of Clinical Pediatrics
SciTechnol Mediakit Research Journal of Clinical Pediatrics Research and Reports on MatheMatics www.scitechnol.com www.scitechnol.com Our Vision To publish, promote and disseminate the work of medical
More informationPharmaceuticals and Biotechnology
ABCD Pharmaceuticals and yet are quickly accessible from one central location. 7 Gain a competitive advantage 7 Facilitate product research and development 7 Raise return on investment Pharmaceuticals
More informationCurrent Market Dynamics and Future Vision of the Care Cycle
Current Market Dynamics and Future Vision of the Care Cycle Tim Irish Analysts Meeting June 15 th, 2005 Overview Market and Customer trends The Care Cycle and Molecular Medicine 2 Healthcare is the world
More informationAmerican Association of Pharmaceutical Scientists (AAPS)
American Association of Pharmaceutical Scientists (AAPS) AAPS, King Street, Alexandria, VA, USA* he American Association of Pharmaceu- Scientists (AAPS), founded in 1986, Ttical is an individual membership
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationAsterand Bioscience Strategic Alliances
Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in
More informationS-BIOMEDIC. Company Profile
S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome a habitat of billions of beneficial and harmful
More informationVisit our Career Flowchart to get more information on some of these career paths.
Visit our Career Flowchart to get more information on some of these career paths. Academic Research Faculty: This career path consists of university or college professors who conduct research. They select
More informationFrom Bench To Clinic : a personal journey Career Research Advancement Focused Training
From Bench To Clinic : a personal journey Career Research Advancement Focused Training February 13, 2018 Irina Tcherepanova Ph.D. Vice President of Translational Medicine Argos Therapeutics Inc. FDA view
More informationBIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS
BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS Supported By: Organised By: PROGRAMME OVERVIEW BIOLOGICS MAKE UP MORE THAN 1,000 MEDICINES AND VACCINES THAT TARGET MORE THAN 100 DISEASES. Unlike medicines
More informationNew test for transplant rejection on the horizon
December 6, 2004 New test for transplant rejection on the horizon Vancouver Researchers at St. Paul s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate
More informationMedical Biotechnology
Medical Biotechnology The graduates of the new course would be equipped with skills and knowledge to work not only in the traditional biotechnology and biomedical companies and laboratories, but also in
More informationBIOMEDICAL RESEARCH CENTRES
Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
More informationFINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts
GHTF/SG5/N6:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts Authoring Group: Study Group 5 of the Global Harmonization
More informationPIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA
PIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA MISSION & VISION Prof. Kelly Chibale H3D Director Vision To be the leading organisation for integrated drug discovery and development on the African continent.
More informationLooking for clinical trial in dermatology field
Technology Request Summary Looking for clinical trial in dermatology field A French company specialized in cosmetics have patented a new formulation for one of its product. The owner of the company would
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationFast Track Drug Development The Clinical (Caleidoscopic) Perspective
20 Years AGAH, Annual Meeting, Hamburg 21.-23. February 2010 Fast Track Drug Development The Clinical (Caleidoscopic) Perspective Fritz R. Bühler, MD ECPM, University of Basel European Innovative Medicine
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationMay 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250
DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.
More information